Revive Therapeutics Ltd Stock Price, News & Analysis

Revive Therapeutics (OTCQB: RVVTF) has announced an extension of its private placement offering. The company aims to raise up to $650,000 through the issuance of up to 30,952,381 units at $0.021 per unit. Each unit includes one common share and one warrant exercisable at $0.05 for 36 months.

The company has already completed a first tranche in August 2025, raising $60,900 through 2,900,000 units, leaving $589,000 worth of units available. The proceeds will be used for working capital and trade payables settlement. The securities will have a four-month and one-day hold period from issuance.

Revive Therapeutics (OTCQB: RVVTF) has completed the first tranche of its private placement offering, raising $60,900 through the issuance of 2.9 million units at $0.021 per unit. Additionally, the company settled $67,400 in debt through the issuance of 3.2 million units at the same price.

Each unit consists of one common share and one warrant exercisable at $0.05 for 36 months. The company also issued 100,000 compensation options to an investment dealer. The proceeds will be used for working capital and trade payables, with securities subject to a hold period until December 9, 2025.

Revive Therapeutics (OTCQB: RVVTF) has announced a proposed private placement offering of up to 30,952,381 units at $0.021 per unit, aiming to raise gross proceeds of up to $650,000. Additionally, the company plans to settle a $67,400 debt through the issuance of 3,209,523 units at the same price.

Each unit includes one common share and one warrant, with warrants exercisable at $0.05 per share for 36 months. The proceeds will be used for working capital and trade payables. The offering may close in multiple tranches, with securities subject to a four-month hold period.

Revive Therapeutics (OTCQB: RVVTF) has issued a clarification regarding its ongoing research study of Bucillamine as a potential nerve agent countermeasure. The study, conducted in partnership with Defence R&D Canada – Suffield Research Centre (DRDC), is investigating compounds that could mitigate nerve agent-induced brain injury.

The research is scheduled to continue through September 2025. Results will only be released with DRDC's explicit authorization. The company emphasized that any future research collaborations with DRDC would only be considered after the current study's completion and dependent on satisfactory results.

Revive Therapeutics (OTCQB: RVVTF) is nearing completion of a crucial study evaluating Bucillamine as a nerve agent countermeasure in partnership with Defence R&D Canada (DRDC). The study is set to conclude by September 2025, with potential Health Canada approval for strategic stockpiling by 2026.

Bucillamine, a thiol-based drug with proven safety profile, works by replenishing glutathione to protect the brain and organs from toxic exposures. The company aims to expand its applications to include traumatic brain injury (TBI) and viral infections. The successful development could position Revive for significant government stockpiling contracts with Canada and its "Five Eyes" intelligence partners.

Revive Therapeutics (RVVTF) announces advancement in developing a next-generation lyophilized formulation of Bucillamine in collaboration with the University of Waterloo. The company is positioning New Bucillamine to target public health emergencies, including pandemic influenza and emerging infectious diseases. Bucillamine, which already holds FDA Orphan Drug Designation for ischemia-reperfusion injury in organ transplantation since 2022, shows promise in enhancing solid tumor treatments. The company is working with Defence R&D Canada to evaluate Bucillamine for nerve agent exposure, with results expected by June 2025. Clinical trials could begin in H2 2025, pending positive results. Revive is pursuing various FDA incentives and exploring partnerships to accelerate development and commercialization.

Revive Therapeutics (RVVTF) has provided an update on its research study of Bucillamine as a potential treatment for nerve agent exposure, conducted in partnership with Defence R&D Canada – Suffield Research Centre (DRDC). The study is scheduled to conclude by June 2025, focusing on GABA receptor antibodies and data confirmation. Positive results could lead to human clinical trials in the second half of 2025, seeking FDA and Health Canada approvals for nerve agent and organophosphate pesticide poisoning treatment.

Bucillamine, which is a more potent antioxidant than n-acetylcysteine (NAC), shows potential in protecting GABA(A) receptors and improving anticonvulsant therapies' effectiveness while reducing bleeding risks associated with NAC. The research also explores Bucillamine's applications in traumatic brain injury and viral infections.

Revive Therapeutics (OTCQB: RVVTF) has announced a proposed shares for debt transaction to settle $150,000 in payables to arm's length parties through the issuance of 6,000,000 common shares at $0.025 per share. The issue price is calculated based on the 20-day VWAP of shares traded on the CSE.

The company aims to preserve cash for ongoing operations through this debt settlement. The transaction is subject to customary closing conditions, with shares to be issued having a four-month and one-day hold period from issuance date.

Revive Therapeutics (OTCQB: RVVTF) has been approached by a prominent U.S. University Cancer Institute researcher to investigate Bucillamine's potential in cancer treatment, specifically for enhancing anti-tumor effects in advanced solid tumors. The research would be supported by NIH and other government funding.

The investigation builds on existing partnerships, including one with Defence R&D Canada – Suffield Research Centre, which is evaluating Bucillamine for nerve agent exposure treatment. The cancer research focuses on Bucillamine's role as a thiol donor that could neutralize reactive oxygen species and replenish reduced glutathione in the tumor microenvironment (TME), potentially amplifying antitumor effects.

This approach aims to address challenges in nucleic acid-based therapies, particularly regarding drug delivery and stability in the TME, which is characterized by low oxygen levels and elevated reduced glutathione.